Skip to main content
Qurient Co., Ltd. logo

Qurient Co., Ltd. — Investor Relations & Filings

Ticker · 115180 ISIN · KR7115180002 KO Professional, scientific and technical activities
Open in API
Filings indexed 437 across all filing types
Latest filing 2026-03-18 Audit Report / Informat…
Country KR South Korea
Listing KO 115180

About Qurient Co., Ltd.

http://www.qurient.com/

Qurient Co., Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for unmet medical needs. The company operates on a proprietary 'Network R&D' model, a virtual approach that manages drug development programs from early discovery through clinical phases. Its pipeline includes Adrixetinib for chronic graft-versus-host disease (cGvHD), Telacebec for the treatment of tuberculosis, and a next-generation dual-payload Antibody-Drug Conjugate (ADC) platform for oncology. Qurient advances its portfolio through global clinical trials and strategic collaborations to address critical diseases.

Recent filings

Filing Released Lang Actions
[기재정정]사업보고서 (2023.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'Curieent' (큐리언트) for the fiscal year ending December 31, 2023. It includes the independent auditor's opinion, financial statements (balance sheet, income statement, etc.), and notes. It explicitly mentions a re-issuance of the audit report due to financial statement restatements. This fits the definition of an Audit Report (AR) as it is a standalone audit document rather than a full Annual Report (10-K). FY 2023
2026-03-18 Korean
[기재정정]사업보고서 (2024.12)
Audit Report / Information Classification · 100% confidence The document is a 'Consolidated Audit Report' (연결감사보고서) for the company 'Curieent' (큐리언트). It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity), and notes to the financial statements. It explicitly mentions a restatement of financial statements due to an overstatement of derivative assets. Since this is a formal, comprehensive audit report detailing financial performance and accounting adjustments, it falls under the 'Audit Report / Information' category. FY 2024
2026-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 99% confidence The document is a formal regulatory filing titled 'Audit Report Submission' (감사보고서 제출) from the company Curient. It provides a summary of the audit opinion (unqualified/appropriate), key financial data (assets, liabilities, equity, revenue, operating profit), and specific financial ratios (capital impairment, operating loss, etc.) for the fiscal year ending 2025-12-31. While it contains financial data, it is a structured regulatory disclosure of the audit results rather than the full Annual Report (10-K) or a simple announcement of report publication (RPA). Given the specific nature of audit opinion disclosures in the Korean market, this fits best under the Audit Report/Information category. FY 2025
2026-03-18 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (Proxy Solicitation & Information Statement). It contains information regarding the upcoming Annual General Meeting, including the purpose of the meeting, proxy solicitation details, and financial statements (balance sheet, income statement, etc.) provided as reference materials for shareholders to exercise their voting rights. It is not an Annual Report (10-K) itself, but rather a proxy statement for the meeting.
2026-03-11 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Qurient Co., Ltd. It includes the meeting agenda, details on voting procedures (including electronic voting), and management reference materials (business overview, financial statements, and board activity). This document is a standard proxy statement/notice package sent to shareholders to inform them of the upcoming Annual General Meeting (AGM) and to solicit their votes. In the context of the provided categories, this fits the definition of a Proxy Solicitation & Information Statement (PSI).
2026-03-11 Korean
[기재정정]파생상품거래손실발생
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a Korean company (Qurient) regarding a correction (정정신고) to a previously disclosed report about derivative transaction losses. It details specific financial adjustments made during the audit process. Since it is a regulatory announcement regarding a specific financial event (derivative loss) and does not fit into categories like Annual Reports or Earnings Releases, it falls under the general regulatory filing category.
2026-03-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.